JP2014176733A - ステントを編組するためのマンドレル - Google Patents
ステントを編組するためのマンドレル Download PDFInfo
- Publication number
- JP2014176733A JP2014176733A JP2014094637A JP2014094637A JP2014176733A JP 2014176733 A JP2014176733 A JP 2014176733A JP 2014094637 A JP2014094637 A JP 2014094637A JP 2014094637 A JP2014094637 A JP 2014094637A JP 2014176733 A JP2014176733 A JP 2014176733A
- Authority
- JP
- Japan
- Prior art keywords
- mandrel
- stent
- filament
- braided
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009954 braiding Methods 0.000 title claims abstract description 104
- 230000007704 transition Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 description 61
- 239000000969 carrier Substances 0.000 description 37
- 229920000642 polymer Polymers 0.000 description 35
- 239000000463 material Substances 0.000 description 25
- 230000033001 locomotion Effects 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 13
- -1 polyethylene terephthalate Polymers 0.000 description 13
- 238000000576 coating method Methods 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 229910001000 nickel titanium Inorganic materials 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 7
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 229920001432 poly(L-lactide) Polymers 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 239000004632 polycaprolactone Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 description 4
- 239000005020 polyethylene terephthalate Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 229910052715 tantalum Inorganic materials 0.000 description 3
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 102000003908 Cathepsin D Human genes 0.000 description 2
- 108090000258 Cathepsin D Proteins 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960000610 enoxaparin Drugs 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- 150000003883 epothilone derivatives Chemical class 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VNDNKFJKUBLYQB-UHFFFAOYSA-N 2-(4-amino-6-chloro-5-oxohexyl)guanidine Chemical compound ClCC(=O)C(N)CCCN=C(N)N VNDNKFJKUBLYQB-UHFFFAOYSA-N 0.000 description 1
- UHKPXKGJFOKCGG-UHFFFAOYSA-N 2-methylprop-1-ene;styrene Chemical compound CC(C)=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 UHKPXKGJFOKCGG-UHFFFAOYSA-N 0.000 description 1
- ASVKKRLMJCWVQF-UHFFFAOYSA-N 3-buten-1-amine Chemical group NCCC=C ASVKKRLMJCWVQF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 102000011262 beta-Adrenergic Receptor Kinases Human genes 0.000 description 1
- 108010037997 beta-Adrenergic Receptor Kinases Proteins 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(III) oxide Inorganic materials O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- IQBJFLXHQFMQRP-UHFFFAOYSA-K calcium;zinc;phosphate Chemical compound [Ca+2].[Zn+2].[O-]P([O-])([O-])=O IQBJFLXHQFMQRP-UHFFFAOYSA-K 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 description 1
- 229960002006 linsidomine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910000734 martensite Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- KYTZHLUVELPASH-UHFFFAOYSA-N naphthalene-1,2-dicarboxylic acid Chemical class C1=CC=CC2=C(C(O)=O)C(C(=O)O)=CC=C21 KYTZHLUVELPASH-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 102000005681 phospholamban Human genes 0.000 description 1
- 108010059929 phospholamban Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920006210 poly(glycolide-co-caprolactone) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920003009 polyurethane dispersion Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006216 polyvinyl aromatic Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04C—BRAIDING OR MANUFACTURE OF LACE, INCLUDING BOBBIN-NET OR CARBONISED LACE; BRAIDING MACHINES; BRAID; LACE
- D04C3/00—Braiding or lacing machines
- D04C3/48—Auxiliary devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- D—TEXTILES; PAPER
- D02—YARNS; MECHANICAL FINISHING OF YARNS OR ROPES; WARPING OR BEAMING
- D02G—CRIMPING OR CURLING FIBRES, FILAMENTS, THREADS, OR YARNS; YARNS OR THREADS
- D02G1/00—Producing crimped or curled fibres, filaments, yarns, or threads, giving them latent characteristics
- D02G1/02—Producing crimped or curled fibres, filaments, yarns, or threads, giving them latent characteristics by twisting, fixing the twist and backtwisting, i.e. by imparting false twist
-
- D—TEXTILES; PAPER
- D02—YARNS; MECHANICAL FINISHING OF YARNS OR ROPES; WARPING OR BEAMING
- D02G—CRIMPING OR CURLING FIBRES, FILAMENTS, THREADS, OR YARNS; YARNS OR THREADS
- D02G3/00—Yarns or threads, e.g. fancy yarns; Processes or apparatus for the production thereof, not otherwise provided for
- D02G3/22—Yarns or threads characterised by constructional features, e.g. blending, filament/fibre
- D02G3/26—Yarns or threads characterised by constructional features, e.g. blending, filament/fibre with characteristics dependent on the amount or direction of twist
- D02G3/28—Doubled, plied, or cabled threads
-
- D—TEXTILES; PAPER
- D02—YARNS; MECHANICAL FINISHING OF YARNS OR ROPES; WARPING OR BEAMING
- D02G—CRIMPING OR CURLING FIBRES, FILAMENTS, THREADS, OR YARNS; YARNS OR THREADS
- D02G3/00—Yarns or threads, e.g. fancy yarns; Processes or apparatus for the production thereof, not otherwise provided for
- D02G3/44—Yarns or threads characterised by the purpose for which they are designed
- D02G3/448—Yarns or threads for use in medical applications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04C—BRAIDING OR MANUFACTURE OF LACE, INCLUDING BOBBIN-NET OR CARBONISED LACE; BRAIDING MACHINES; BRAID; LACE
- D04C1/00—Braid or lace, e.g. pillow-lace; Processes for the manufacture thereof
- D04C1/06—Braid or lace serving particular purposes
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04C—BRAIDING OR MANUFACTURE OF LACE, INCLUDING BOBBIN-NET OR CARBONISED LACE; BRAIDING MACHINES; BRAID; LACE
- D04C3/00—Braiding or lacing machines
- D04C3/02—Braiding or lacing machines with spool carriers guided by track plates or by bobbin heads exclusively
- D04C3/14—Spool carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91508—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a difference in amplitude along the band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91516—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other the meander having a change in frequency along the band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91525—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other within the whole structure different bands showing different meander characteristics, e.g. frequency or amplitude
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04C—BRAIDING OR MANUFACTURE OF LACE, INCLUDING BOBBIN-NET OR CARBONISED LACE; BRAIDING MACHINES; BRAID; LACE
- D04C1/00—Braid or lace, e.g. pillow-lace; Processes for the manufacture thereof
- D04C1/02—Braid or lace, e.g. pillow-lace; Processes for the manufacture thereof made from particular materials
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
- D10B2509/06—Vascular grafts; stents
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Textile Engineering (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mechanical Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Prostheses (AREA)
- Woven Fabrics (AREA)
Abstract
【解決手段】いくつかのステントフィラメントからステントを編組するためのマンドレル22は、筒状部材と、その先端44において周長に沿って配置された複数の固定突出部48と、基端46と固定突出部との間において筒状部材の外側表面から突起した複数の突出部52および56とを備え、隣接する突起した突出部は、ステントフィラメントの少なくとも1つを受承するためのチャネルを形成し、突起した突出部の少なくとも1つは四角錐の形状をなす。
【選択図】図5
Description
典型的な細胞には、幹細胞、始原細胞、血管内皮細胞、成人心筋細胞、および平滑筋細胞が挙げられる。細胞は、ヒト起源のもの(自己由来もしくは同種異型)であってもよいし、動物供給源(異種)由来であってもよいし、または遺伝子操作されたものであってもよい。細胞の非限定的な例には、サイドポピュレーション(SP)細胞、系統陰性(lineage negative)(Lin−)細胞、例えばLin−CD34−、Lin−CD34+、Lin−cKit+、間葉系幹細胞、例えば5‐azaを伴った間葉系幹細胞、臍帯血細胞、心臓またはその他の組織由来の幹細胞、全骨髄、骨髄単核細胞、内皮始原細胞、骨格筋筋芽細胞または衛星細胞、筋肉由来細胞、G0細胞、内皮細胞、成人心筋細胞、繊維芽細胞、平滑筋細胞、成人心臓線維芽細胞+5‐aza、遺伝子組換え細胞、組織工学移植片、MyoD瘢痕組織由来線維芽細胞、ペースメーカー細胞、胚性幹細胞クローン、胚性幹細胞、胎児または新生児の細胞、免疫学的にマスクされた細胞、および奇形腫由来細胞が挙げられる。
上記の治療薬のうち任意のものが、ステント24上のポリマーコーティングの中に組み込まれてもよいし、ステント24上のポリマーコーティングの上に適用されてもよい。ポリマーコーティングのポリマーは生物分解性であってもよいし、非生物分解性であってもよい。適切な非生物分解性ポリマーの非限定的な例には、ポリスチレン;ポリスチレン無水マレイン酸;ポリイソブチレンコポリマー、例えばスチレン‐イソブチレン‐スチレンブロックコポリマー(SIBS)およびスチレン‐エチレン/ブチレン‐スチレン(SEBS)ブロックコポリマー;ポリビニルピロリドン、例えば架橋型ポリビニルピロリドン;ポリビニルアルコール、EVAのようなビニルモノマーのコポリマー;ポリビニルエーテル;ポリビニル芳香族;ポリエチレンオキシド;ポリエステル、例えばポリエチレンテレフタレート;ポリアミド;ポリアクリルアミド、例えばポリ(メチルメタクリラート‐ブチルアセタート‐メチルメタクリラート)ブロックコポリマー;ポリエーテル、例えばポリエーテルスルホン;ポリアルキレン、例えばポリプロピレン、ポリエチレンおよび高分子ポリエチレン;ポリウレタン;ポリカーボネート、シリコーン;シロキサンポリマー;セルロースポリマー、例えば酢酸セルロース;ポリマーディスパージョン、例えばポリウレタンディスパージョン(BAYHYDROL(登録商標));スクワレン乳剤;ならびに前述のうち任意のものの混合物およびコポリマーが挙げられる。
コーティングは、典型的には厚さ約1〜約50ミクロンである。医療用デバイス上にポリマーコーティングの多重層を適用することも、本発明の範囲内にある。そのような多重層は同じ治療薬を含有しても異なる治療薬を含有してもよいし、かつ/または同じポリマーを含有しても異なるポリマーを含有してもよい。様々な放出動態を作成するためにポリマーまたは治療薬のうち少なくともいずれか一方の種類、厚さ、およびその他の特性を選択する方法は、当業者には良く知られている。
実施形態3. 引張型編組用キャリアはそれぞれ伸縮自在のキャリアフィラメントを含んでなることと、さらに、ステップ(e)は、1つのフィラメントの対向する両端部のうちの一方を引張型編組用キャリアのうちの1つの伸縮自在のキャリアフィラメントに固定することを含み、かつ、ステップ(f)は、1つのフィラメントの対向する両端部のうちの他方を第2の引張型編組用キャリアの伸縮自在のキャリアフィラメントに対して固定することを含むこととを特徴とする、実施形態1に記載の方法。
実施形態7. 引張型編組用キャリアの数はフィラメントの数の約2倍である、実施形態1に記載の方法。
実施形態9. マンドレルは複数の溝部を含んでなることと、さらにフィラメントはステップ(h)〜(i)の編組中に溝部の中に配置されることとを特徴とする、実施形態1に記載の方法。
実施形態11. 編組用マンドレルの先端の固定突出部は、フック、ピン、タブ、スクリュー、およびこれらの組み合わせからなる群から選択される、実施形態1に記載の方法。
実施形態13. 編組用マンドレルの先端は、固定突出部が配置されたカラーをさらに含んでなることと、さらに、固定突出部は、フック、ピン、タブ、スクリュー、およびこれらの組み合わせからなる群から選択されることとを特徴とする、実施形態1に記載の方法。
実施形態16. マンドレルは、第1の直径を有する第1の部分および第2の直径を有する第2の部分を含んでなることと、第1の直径は第2の直径とは異なることと、前記第1および第2の部分全体に溝部が配置されることとを特徴とし、さらに、一定力編組用キャリアからフィラメントへと張力を付与して、交差している編組フィラメントの間の編組角度が第1および第2の部分においてほぼ等しくなるようにするステップを含んでなる、実施形態9に記載の方法。
実施形態19. フィラメントはニチノールを含んでなる金属フィラメントである、実施形態1に記載の方法。
実施形態22. 編組用キャリアは一定力キャリアであることと、さらに、フィラメントの端部は、一定力キャリアへのフィラメントの巻き取りを伴わずに、一定力キャリアに対して固定可能なように配置可能であることとを特徴とする、実施形態20に記載の方法。
実施形態24. 一定の張力は約0.25重量ポンド(1.1ニュートン)〜約5重量ポンド(22.2ニュートン)である、実施形態20に記載の方法。
実施形態27. 約0.25重量ポンド(1.1ニュートン)〜約5重量ポンド(22.2ニュートン)の一定の張力を付与するステップをさらに含んでなる、実施形態25に記載の方法。
実施形態31. 第1の部分、第2の部分、および移行部分における編組角度は全て互いに1度以内にある、実施形態29に記載の編組ステント。
実施形態33. 第1の部分、第2の部分、または移行部分における編組角度のうち少なくとも1つは、他の部分の編組角度とは異なっている、実施形態28に記載の編組ステント。
実施形態35. フィラメントはニチノールを含んでなる金属フィラメントである、実施形態28に記載の編組ステント。
実施形態38. 間隔を置いて配置された複数の突出部をさらに含んでなり、該突出部の間の間隔が、長尺状部材に角度をなして配置された複数の溝部を画成する、実施形態36に記載の編組用マンドレル。
実施形態40. 管状部材の先端に配置されたカラーをさらに含んでなり、固定突出部はカラーの上に配置される、実施形態36に記載の編組用マンドレル。
実施形態42. 管状部材はほぼ一定の直径を有する、実施形態36に記載の編組用マンドレル。
実施形態44. ステップ(e)は、その1つのフィラメントがその1つの引張型編組用キャリアに巻き取られることなく実施され、かつ、ステップ(f)は、その1つのフィラメントが第2の引張型編組用キャリアへ巻き取られることなく実施される、実施形態1に記載の方法。
Claims (7)
- いくつかのステントフィラメント(20)からステント(24)を編組するためのマンドレル(22)であって:
基端(46)から先端(44)に向かって長手方向に延びる外側表面と周長とを有する筒状部材と、
先端(44)において周長に沿って配置された複数の固定突出部(48)と、
基端(46)と固定突出部(48)との間において筒状部材の外側表面から突起した複数の突出部(52,56)と、を備え、
隣接する突起した突出部は、ステントフィラメントの少なくとも1つを受承するためのチャネルを形成し、
突起した突出部の少なくとも1つは、四角錐の形状をなす、マンドレル。 - 突起した突出部の少なくとも1つは、頂部が切断されているかまたは丸みを帯びている上部を有する、請求項1に記載のマンドレル。
- 固定突出部は、スクリュー、ピン、タブおよび移動止めからなる群から選択される、請求項1に記載のマンドレル。
- 固定突出部の少なくとも1つは、丸面を有する突起タブである、請求項1に記載のマンドレル。
- 筒状部材は先端側部分および長手方向に延びる部分を含み、先端側部分は先端と長手方向に延びる部分との間にあり、長手方向に延びる部分は先端側部分と基端との間にある、請求項1に記載のマンドレル。
- 先端側部分は長手方向に延びる部分よりも大きい直径を有する、請求項5に記載のマンドレル。
- 先端側部分と長手方向に延びる部分との間に移行領域をさらに含む、請求項5に記載のマンドレル。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14730709P | 2009-01-26 | 2009-01-26 | |
US61/147,307 | 2009-01-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011548215A Division JP5640018B2 (ja) | 2009-01-26 | 2010-01-26 | ステントを編組する方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016006898A Division JP6215367B2 (ja) | 2009-01-26 | 2016-01-18 | 編組用マンドレル |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014176733A true JP2014176733A (ja) | 2014-09-25 |
JP5873890B2 JP5873890B2 (ja) | 2016-03-01 |
Family
ID=42354798
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011548215A Active JP5640018B2 (ja) | 2009-01-26 | 2010-01-26 | ステントを編組する方法 |
JP2014094637A Active JP5873890B2 (ja) | 2009-01-26 | 2014-05-01 | ステントを編組するためのマンドレル |
JP2016006898A Active JP6215367B2 (ja) | 2009-01-26 | 2016-01-18 | 編組用マンドレル |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011548215A Active JP5640018B2 (ja) | 2009-01-26 | 2010-01-26 | ステントを編組する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016006898A Active JP6215367B2 (ja) | 2009-01-26 | 2016-01-18 | 編組用マンドレル |
Country Status (9)
Country | Link |
---|---|
US (9) | US8151682B2 (ja) |
EP (3) | EP3998379A1 (ja) |
JP (3) | JP5640018B2 (ja) |
KR (4) | KR101663787B1 (ja) |
CN (2) | CN102362023B (ja) |
AU (1) | AU2010206532B2 (ja) |
CA (1) | CA2750763C (ja) |
ES (2) | ES2701650T3 (ja) |
WO (1) | WO2010085794A2 (ja) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632241B1 (en) * | 2000-03-22 | 2003-10-14 | Endovascular Technologies, Inc. | Self-expanding, pseudo-braided intravascular device |
US7905904B2 (en) | 2006-02-03 | 2011-03-15 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US8118836B2 (en) | 2004-11-05 | 2012-02-21 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US8128658B2 (en) | 2004-11-05 | 2012-03-06 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to bone |
US7749250B2 (en) | 2006-02-03 | 2010-07-06 | Biomet Sports Medicine, Llc | Soft tissue repair assembly and associated method |
US8303604B2 (en) | 2004-11-05 | 2012-11-06 | Biomet Sports Medicine, Llc | Soft tissue repair device and method |
US7909851B2 (en) | 2006-02-03 | 2011-03-22 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US8088130B2 (en) | 2006-02-03 | 2012-01-03 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US7601165B2 (en) | 2006-09-29 | 2009-10-13 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable suture loop |
US8137382B2 (en) | 2004-11-05 | 2012-03-20 | Biomet Sports Medicine, Llc | Method and apparatus for coupling anatomical features |
US9017381B2 (en) | 2007-04-10 | 2015-04-28 | Biomet Sports Medicine, Llc | Adjustable knotless loops |
US8361113B2 (en) | 2006-02-03 | 2013-01-29 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US8298262B2 (en) | 2006-02-03 | 2012-10-30 | Biomet Sports Medicine, Llc | Method for tissue fixation |
US10517587B2 (en) | 2006-02-03 | 2019-12-31 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US8562647B2 (en) | 2006-09-29 | 2013-10-22 | Biomet Sports Medicine, Llc | Method and apparatus for securing soft tissue to bone |
US8936621B2 (en) | 2006-02-03 | 2015-01-20 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US8597327B2 (en) | 2006-02-03 | 2013-12-03 | Biomet Manufacturing, Llc | Method and apparatus for sternal closure |
US8562645B2 (en) | 2006-09-29 | 2013-10-22 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US8652171B2 (en) | 2006-02-03 | 2014-02-18 | Biomet Sports Medicine, Llc | Method and apparatus for soft tissue fixation |
US11259792B2 (en) | 2006-02-03 | 2022-03-01 | Biomet Sports Medicine, Llc | Method and apparatus for coupling anatomical features |
US8968364B2 (en) | 2006-02-03 | 2015-03-03 | Biomet Sports Medicine, Llc | Method and apparatus for fixation of an ACL graft |
US9078644B2 (en) | 2006-09-29 | 2015-07-14 | Biomet Sports Medicine, Llc | Fracture fixation device |
US8801783B2 (en) | 2006-09-29 | 2014-08-12 | Biomet Sports Medicine, Llc | Prosthetic ligament system for knee joint |
US11311287B2 (en) | 2006-02-03 | 2022-04-26 | Biomet Sports Medicine, Llc | Method for tissue fixation |
US8672969B2 (en) | 2006-09-29 | 2014-03-18 | Biomet Sports Medicine, Llc | Fracture fixation device |
US11259794B2 (en) | 2006-09-29 | 2022-03-01 | Biomet Sports Medicine, Llc | Method for implanting soft tissue |
CN105943208B (zh) | 2007-06-25 | 2019-02-15 | 微仙美国有限公司 | 自扩展假体 |
US9034007B2 (en) | 2007-09-21 | 2015-05-19 | Insera Therapeutics, Inc. | Distal embolic protection devices with a variable thickness microguidewire and methods for their use |
US8623071B2 (en) * | 2008-01-07 | 2014-01-07 | DePuy Synthes Products, LLC | Radiopaque super-elastic intravascular stent |
US8151682B2 (en) * | 2009-01-26 | 2012-04-10 | Boston Scientific Scimed, Inc. | Atraumatic stent and method and apparatus for making the same |
US12096928B2 (en) | 2009-05-29 | 2024-09-24 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
FR2952653B1 (fr) * | 2009-11-18 | 2011-12-09 | Commissariat Energie Atomique | Architecture fibreuse tubulaire fermee et procede de fabrication |
WO2011137043A1 (en) | 2010-04-30 | 2011-11-03 | Boston Scientific Scimed, Inc. | Apparatus and method for manufacturing a single wire stent |
US10265200B2 (en) * | 2010-08-10 | 2019-04-23 | Cook Medical Technologies Llc | Medical prostheses having bundled and non-bundled regions |
DE102010052737B3 (de) * | 2010-11-26 | 2012-04-19 | Daimler Ag | Modulare Fertigungsvorrichtung für integrale Faser-Halbzeuge und Verfahren zur Herstellung von Endlosfaser-Verbundbauteilen aus integralen Faserverbund-Halbzeugen mit einer Hohlkörperstruktur |
KR101330825B1 (ko) * | 2011-01-14 | 2013-11-15 | 신경민 | 굽힘 특성이 양호한 스텐트의 제조방법과 그 스텐트 |
US9867690B2 (en) | 2011-02-09 | 2018-01-16 | Neograft Technologies, Inc. | System and mandrel for creating graft devices |
US8511214B2 (en) | 2011-04-21 | 2013-08-20 | Aga Medical Corporation | Tubular structure and method for making the same |
EP2751323B1 (en) * | 2011-09-01 | 2020-03-25 | Cook Medical Technologies LLC | Method of forming a braided helical wire stent |
JP6133307B2 (ja) | 2011-10-17 | 2017-05-24 | シークエント メディカル インコーポレイテッド | 編組機及び使用方法 |
US8261648B1 (en) | 2011-10-17 | 2012-09-11 | Sequent Medical Inc. | Braiding mechanism and methods of use |
EP2757960B1 (en) * | 2011-10-27 | 2022-06-01 | Occlutech Holding AG | A medical implant and a method of manufacturing a 3d fabric of strands for forming a medical implant |
US9357991B2 (en) | 2011-11-03 | 2016-06-07 | Biomet Sports Medicine, Llc | Method and apparatus for stitching tendons |
US9314241B2 (en) | 2011-11-10 | 2016-04-19 | Biomet Sports Medicine, Llc | Apparatus for coupling soft tissue to a bone |
US9381013B2 (en) | 2011-11-10 | 2016-07-05 | Biomet Sports Medicine, Llc | Method for coupling soft tissue to a bone |
CZ303606B6 (cs) * | 2012-02-27 | 2013-01-02 | Ella-Cs, S.R.O. | Zpusob výroby stentu a stent vyrobený tímto zpusobem |
CN104427956B (zh) | 2012-07-13 | 2016-09-28 | 波士顿科学国际有限公司 | 用于经导管递送的可收缩笼球人工瓣膜 |
KR101381800B1 (ko) * | 2012-07-16 | 2014-04-07 | 박춘오 | 스텐트 제조 장치 |
CN102973341B (zh) * | 2012-11-08 | 2015-06-17 | 先健科技(深圳)有限公司 | 一种编织的自膨式管腔支架及其制作方法 |
US9561064B2 (en) | 2012-11-21 | 2017-02-07 | Pioneer Surgical Technology, Inc. | Bone plate system and method |
US10765465B2 (en) | 2012-11-21 | 2020-09-08 | A&E Advanced Closure Systems, Llc | Tensioning instrument |
KR20140094144A (ko) | 2013-01-21 | 2014-07-30 | 주식회사 엠아이텍 | 이탈 방지용 스텐트, 제조 장치 및 그 제조 방법 |
US9918827B2 (en) | 2013-03-14 | 2018-03-20 | Biomet Sports Medicine, Llc | Scaffold for spring ligament repair |
US9284668B2 (en) | 2013-03-14 | 2016-03-15 | Medos International Sárl | Continuous braided closed loop implant |
US8715314B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment measurement methods |
US8715315B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment systems |
US8679150B1 (en) | 2013-03-15 | 2014-03-25 | Insera Therapeutics, Inc. | Shape-set textile structure based mechanical thrombectomy methods |
US9585695B2 (en) | 2013-03-15 | 2017-03-07 | Woven Orthopedic Technologies, Llc | Surgical screw hole liner devices and related methods |
CN109730806B (zh) | 2013-03-15 | 2023-01-24 | 伊瑟拉医疗公司 | 脉管治疗装置和方法 |
DE102013103176A1 (de) * | 2013-03-28 | 2014-10-02 | Acandis Gmbh & Co. Kg | Verfahren zur Herstellung eines patientenspezifischen Implantats |
JP6196808B2 (ja) * | 2013-05-21 | 2017-09-13 | 株式会社カネカ | マンドレル |
KR101838824B1 (ko) | 2013-06-25 | 2018-03-14 | 나이키 이노베이트 씨.브이. | 편조형 갑피를 지닌 신발류 물품 |
US10863794B2 (en) | 2013-06-25 | 2020-12-15 | Nike, Inc. | Article of footwear having multiple braided structures |
CA2919384C (en) * | 2013-08-09 | 2018-01-02 | Boston Scientific Scimed, Inc. | Stent designs and methods of manufacture |
US9999454B2 (en) | 2013-12-05 | 2018-06-19 | A&E Advanced Closure Systems, Llc | Bone plate system and method |
US10314635B2 (en) | 2014-05-28 | 2019-06-11 | A&E Advanced Closure Systems, Llc | Tensioning instruments |
US9907593B2 (en) | 2014-08-05 | 2018-03-06 | Woven Orthopedic Technologies, Llc | Woven retention devices, systems and methods |
US8956394B1 (en) | 2014-08-05 | 2015-02-17 | Woven Orthopedic Technologies, Llc | Woven retention devices, systems and methods |
USD745943S1 (en) * | 2014-08-27 | 2015-12-22 | WHG Properties, LLC | Component of a trigger mechanism for a firearm |
US9562731B2 (en) | 2014-08-27 | 2017-02-07 | WHG Properties, LLC | Method for manufacturing a trigger element of a sear mechanism for a firearm |
US9943351B2 (en) | 2014-09-16 | 2018-04-17 | Woven Orthopedic Technologies, Llc | Woven retention devices, systems, packaging, and related methods |
EP4302726A3 (en) * | 2014-10-09 | 2024-03-27 | Boston Scientific Scimed, Inc. | Mandrel and method of forming an expandable stent structure |
USD740427S1 (en) | 2014-10-17 | 2015-10-06 | Woven Orthopedic Technologies, Llc | Orthopedic woven retention device |
US9668544B2 (en) | 2014-12-10 | 2017-06-06 | Nike, Inc. | Last system for articles with braided components |
US9839253B2 (en) | 2014-12-10 | 2017-12-12 | Nike, Inc. | Last system for braiding footwear |
US10674791B2 (en) | 2014-12-10 | 2020-06-09 | Nike, Inc. | Braided article with internal midsole structure |
US20160168769A1 (en) * | 2014-12-12 | 2016-06-16 | Woven Orthopedic Technologies, Llc | Methods and systems for manufacturing woven retention devices |
JP2016116633A (ja) * | 2014-12-19 | 2016-06-30 | テルモ株式会社 | ワイヤ編組型ステント及びその製造方法 |
CN104562427B (zh) * | 2015-01-07 | 2016-09-28 | 浙江理工大学 | 一种用于三维环形编织机芯轴换接方法及其系统 |
KR102541896B1 (ko) | 2015-03-05 | 2023-06-08 | 메리트 메디컬 시스템즈, 인크. | 혈관 보철물 전개 장치 및 사용 방법 |
BR102015011376B1 (pt) | 2015-05-18 | 2023-04-04 | Murilo Pundek Rocha | Brônquio artificial implantável |
US10280538B2 (en) | 2015-05-26 | 2019-05-07 | Nike, Inc. | Braiding machine and method of forming an article incorporating a moving object |
US10555581B2 (en) | 2015-05-26 | 2020-02-11 | Nike, Inc. | Braided upper with multiple materials |
US20160345675A1 (en) | 2015-05-26 | 2016-12-01 | Nike, Inc. | Hybrid Braided Article |
US10060057B2 (en) | 2015-05-26 | 2018-08-28 | Nike, Inc. | Braiding machine with non-circular geometry |
US10238176B2 (en) | 2015-05-26 | 2019-03-26 | Nike, Inc. | Braiding machine and method of forming a braided article using such braiding machine |
WO2017024277A1 (en) | 2015-08-05 | 2017-02-09 | Woven Orthopedic Technologies, Llc | Tapping devices, systems and methods for use in bone tissue |
US11103028B2 (en) | 2015-08-07 | 2021-08-31 | Nike, Inc. | Multi-layered braided article and method of making |
US9920462B2 (en) | 2015-08-07 | 2018-03-20 | Nike, Inc. | Braiding machine with multiple rings of spools |
WO2017031065A1 (en) * | 2015-08-17 | 2017-02-23 | Boston Scientific Scimed, Inc. | Radioactive stent |
US10470906B2 (en) | 2015-09-15 | 2019-11-12 | Merit Medical Systems, Inc. | Implantable device delivery system |
US10004617B2 (en) | 2015-10-20 | 2018-06-26 | Cook Medical Technologies Llc | Woven stent device and manufacturing method |
EP3405145B1 (en) * | 2016-01-22 | 2022-06-22 | Fort Wayne Metals Research Products Corporation | Woven or braided tubular metal construct |
EP3405131B1 (en) | 2016-01-22 | 2023-07-19 | A&E Advanced Closure Systems, LLC | Bone plate having a connector and a connector for a surgical loop |
CN108697423A (zh) | 2016-02-16 | 2018-10-23 | 伊瑟拉医疗公司 | 抽吸装置和锚定的分流装置 |
US10213290B2 (en) | 2016-02-17 | 2019-02-26 | Boston Scientific Scimed, Inc. | Braided stent and method of manufacturing a braided stent |
JP6937327B2 (ja) | 2016-03-17 | 2021-09-22 | スワミナサン ジャヤラマン | 解剖学的構造の閉塞 |
US10390944B2 (en) * | 2016-04-13 | 2019-08-27 | Hlt, Inc. | Braided support structure |
JP6697084B2 (ja) * | 2016-06-03 | 2020-05-20 | 浦易(上海)生物技術有限公司 | 鼻腔ステントの編組成形方法及びこれにより得られるステント |
EP3490475B1 (en) | 2016-07-29 | 2021-05-12 | A&E Advanced Closure Systems, LLC | Surgical cable tensioner |
CA3033080A1 (en) | 2016-09-29 | 2018-04-05 | Merit Medical Systems, Inc. | Pliant members for receiving and aiding in the deployment of vascular prostheses |
CN106498622B (zh) * | 2016-10-08 | 2019-07-23 | 东华大学 | 变截面多边形编织芯模及其装配方法 |
EP3526379B1 (en) | 2016-10-14 | 2021-08-11 | Inceptus Medical, LLC | Braiding machine and methods of use |
JP6072973B1 (ja) * | 2016-10-21 | 2017-02-01 | 株式会社北村製作所 | テンポラリーステントの製造方法 |
US10948249B2 (en) | 2016-10-25 | 2021-03-16 | 22 Evolution Llc | Radial delayed blowback operating system for a firearm including a recoil discharge force attenuation interface between a cam pin and a clearance pocket configured within an upper receiver of the firearm |
US10941993B2 (en) | 2016-10-25 | 2021-03-09 | 22 Evolution Llc | Radial delayed blowback operating system for a firearm incorporating a rotational inducing profile established between bolt lugs and a mating receiving pattern within the upper receiver or a trunnion installed within the receiver |
CN106580516A (zh) * | 2016-11-28 | 2017-04-26 | 上海市徐汇区大华医院 | 一种覆膜给药的可降解胆管支架 |
WO2018107114A1 (en) | 2016-12-09 | 2018-06-14 | Woven Orthopedic Technologies, LLC. | Retention devices, lattices and related systems and methods |
WO2018117788A1 (es) * | 2016-12-20 | 2018-06-28 | Segura Armenta Rolando | Proceso de manufactura de endoprótesis vasculares con control adaptativo de tensión |
CN110573092B (zh) | 2017-02-24 | 2023-04-18 | 因赛普特斯医学有限责任公司 | 血管阻塞装置和方法 |
WO2018170066A1 (en) | 2017-03-15 | 2018-09-20 | Merit Medical Systems, Inc. | Transluminal delivery devices and related kits and methods |
EP3595594B1 (en) | 2017-03-15 | 2024-09-18 | Merit Medical Systems, Inc. | Transluminal stents |
USD836194S1 (en) | 2017-03-21 | 2018-12-18 | Merit Medical Systems, Inc. | Stent deployment device |
US10806210B2 (en) | 2017-05-31 | 2020-10-20 | Nike, Inc. | Braided articles and methods for their manufacture |
US11202483B2 (en) | 2017-05-31 | 2021-12-21 | Nike, Inc. | Braided articles and methods for their manufacture |
US11051573B2 (en) | 2017-05-31 | 2021-07-06 | Nike, Inc. | Braided articles and methods for their manufacture |
WO2019023437A1 (en) * | 2017-07-27 | 2019-01-31 | Boston Scientific Scimed, Inc. | ADJUSTABLE CHUCK FOR FORMING STENT WITH ANTI-MIGRATION FEATURES |
WO2019073901A1 (ja) * | 2017-10-11 | 2019-04-18 | 株式会社 京都医療設計 | 動脈瘤塞栓用の部材 |
EP3695037B1 (en) | 2017-10-14 | 2024-03-27 | Inceptus Medical, LLC | Braiding machine and methods of use |
US10893931B2 (en) * | 2017-10-16 | 2021-01-19 | Amrita Vishwa Vidyapeetham | Strong, flexible, and thrombus-free woven nanotextile based vascular grafts, and method of production thereof |
EP3700474B1 (en) | 2017-10-25 | 2023-08-23 | Boston Scientific Scimed, Inc. | Stent with atraumatic spacer |
WO2019089741A1 (en) | 2017-11-01 | 2019-05-09 | Boston Scientific Scimed, Inc. | Esophageal stent including a valve member |
JP6637477B2 (ja) * | 2017-11-09 | 2020-01-29 | 本田技研工業株式会社 | 軸状複合部材の製造装置および製造方法 |
AU2019218260B2 (en) * | 2018-02-09 | 2022-01-06 | W. L. Gore & Associates, Inc. | Implantable access chamber and associated methods of use |
JP6566071B2 (ja) * | 2018-03-26 | 2019-08-28 | カシオ計算機株式会社 | 情報機器、及びそれらのプログラム並びに金額に関する情報の利用方法 |
EP3890662A1 (en) | 2018-12-04 | 2021-10-13 | Boston Scientific Scimed Inc. | Device for anastomotic bypass |
KR102582640B1 (ko) * | 2019-01-07 | 2023-09-25 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | 이동 방지 특징부를 갖는 스텐트 |
DE102019101238B8 (de) * | 2019-01-17 | 2020-08-06 | Stebo Sondermaschinenbau GmbH & Co. KG | Verfahren zum Herstellen eines geflochtenen Einfadenstents, Vorrichtung und Flechtkern hierfür sowie geflochtener Einfadenstent |
CN110077901A (zh) * | 2019-04-12 | 2019-08-02 | 池州普胜电工材料科技有限公司 | 一种柔韧性玻璃纤维双层套管的编织装置 |
US11419741B2 (en) | 2019-06-17 | 2022-08-23 | Boston Scientific Scimed, Inc. | Covered endoprosthesis with improved branch access |
CN110345185B (zh) * | 2019-07-19 | 2024-05-28 | 北京星际荣耀空间科技股份有限公司 | 一种金属橡胶预制件及其制备和金属橡胶环的制备方法 |
US20210045900A1 (en) * | 2019-08-13 | 2021-02-18 | Stryker Corporation | Stent braid pattern with enhanced radiopacity |
CN110777478B (zh) * | 2019-10-21 | 2021-06-11 | 西安空间无线电技术研究所 | 一种介质丝管状编织的低无缘互调金属网丝制备方法 |
JP6984906B2 (ja) * | 2019-11-13 | 2021-12-22 | 株式会社アイアールメディカル工房 | ステント、ステント前駆体製造装置、及びステント製造方法 |
US11564787B2 (en) | 2019-11-18 | 2023-01-31 | Boston Scientific Scimed, Inc. | Stent with improved anti-migration properties |
USD902407S1 (en) | 2019-11-19 | 2020-11-17 | Pulmair Medical, Inc. | Implantable artificial bronchus |
JP7325047B2 (ja) * | 2020-01-17 | 2023-08-14 | オリンパス株式会社 | 導波管外導体用の丸組紐製紐機および可撓性導波管の製造方法 |
KR102684751B1 (ko) | 2020-02-03 | 2024-07-12 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | 스텐트, 맨드렐 및 이동-방지 특징부를 가진 스텐트를 형성하기 위한 방법 |
WO2022020633A1 (en) | 2020-07-24 | 2022-01-27 | Merit Medical Systems, Inc. | Esophageal stents and related methods |
EP4231973A4 (en) | 2020-10-26 | 2024-10-02 | Merit Medical Systems Inc | HELICAL THREAD ESOPHAGEAL STENT PROSTHESES |
USD954953S1 (en) | 2020-11-03 | 2022-06-14 | Pulmair Medical, Inc. | Implantable artificial bronchus |
CN116801841A (zh) | 2020-12-02 | 2023-09-22 | 波士顿科学国际有限公司 | 具有改进的部署特性的支架 |
DE202020107453U1 (de) | 2020-12-22 | 2022-03-25 | Acandis Gmbh | Stent, insbesondere zur Behandlung von Erkrankungen der Halsschlagader |
EP4277569A1 (en) | 2021-01-15 | 2023-11-22 | Boston Scientific Scimed, Inc. | Covered endoprosthesis with improved branch drainage |
CN118175975A (zh) * | 2021-08-19 | 2024-06-11 | 杭州启明医疗器械股份有限公司 | 热处理模具以及热处理方法 |
CN114767202B (zh) * | 2022-04-24 | 2023-03-24 | 惠州市顺美医疗科技有限公司 | 一种颅内密网支架及其制备方法 |
WO2024064396A2 (en) * | 2022-09-23 | 2024-03-28 | Senso Medical Labs, Ltd. | Advanced functional strands ropes and cables, methods and systems for manufacturing thereof |
KR102526066B1 (ko) * | 2022-09-28 | 2023-04-26 | 엘아이지넥스원 주식회사 | 상변환을 이용한 메쉬 직조 방법 및 이에 의해 직조된 메쉬 |
USD1014758S1 (en) | 2023-04-19 | 2024-02-13 | Pulmair Medical, Inc. | Implantable artificial bronchus |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405377A (en) * | 1992-02-21 | 1995-04-11 | Endotech Ltd. | Intraluminal stent |
JP2001517536A (ja) * | 1997-10-01 | 2001-10-09 | ボストン サイエンティフィック リミテッド | 柔軟な金属ワイヤステント |
JP2002535075A (ja) * | 1999-02-01 | 2002-10-22 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 織物血管内デバイスおよびその製法およびその搬送用装置 |
JP2004519307A (ja) * | 2001-04-04 | 2004-07-02 | テウング メディカル カンパニー リミテッド | 形状記憶合金を用いた可変状態保持型拡張機構およびその製造方法並びに拡張機構製造機 |
US20040193141A1 (en) * | 2003-02-14 | 2004-09-30 | Leopold Eric W. | Intravascular flow modifier and reinforcement device and deployment system for same |
JP2006506201A (ja) * | 2002-11-20 | 2006-02-23 | ユーヌ・ブージェムラン | メッシュ状構造を有した医療用インプラントの製造方法ならびにこの製造方法によって得られたインプラント |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1945195A (en) * | 1930-07-24 | 1934-01-30 | Edgar E Kellems | Method of and apparatus for making cable grips |
US2230723A (en) * | 1938-01-21 | 1941-02-04 | Goodrich Co B F | Hose |
US2557816A (en) * | 1949-12-28 | 1951-06-19 | Dominick Di Palma | Mandrel |
US3881522A (en) * | 1972-09-13 | 1975-05-06 | Kaiser Glass Fiber Corp | Unidirectional webbing material |
JPS5933085B2 (ja) | 1976-12-09 | 1984-08-13 | クラレプラスチツクス株式会社 | 合成樹脂管の製造方法および製造装置 |
US4130046A (en) | 1978-02-15 | 1978-12-19 | Vincent Sokol | Braiding machine with continuous tension filament control |
SE445884B (sv) | 1982-04-30 | 1986-07-28 | Medinvent Sa | Anordning for implantation av en rorformig protes |
US4519290A (en) * | 1983-11-16 | 1985-05-28 | Thiokol Corporation | Braided preform for refractory articles and method of making |
US5037404A (en) * | 1988-11-14 | 1991-08-06 | Cordis Corporation | Catheter having sections of variable torsion characteristics |
US5127919A (en) * | 1988-12-14 | 1992-07-07 | Vascutec Corporation | Woven vascular graft |
US4893543A (en) | 1989-07-05 | 1990-01-16 | Phillips Raymond J | Braiding mandrel for cable grip and strain relief assemblies |
US5035706A (en) | 1989-10-17 | 1991-07-30 | Cook Incorporated | Percutaneous stent and method for retrieval thereof |
US5501133A (en) | 1990-03-29 | 1996-03-26 | Albany International Corp. | Apparatus for making a braid structure |
US7101392B2 (en) | 1992-03-31 | 2006-09-05 | Boston Scientific Corporation | Tubular medical endoprostheses |
JP2559048Y2 (ja) * | 1992-03-31 | 1998-01-14 | 株式会社長田中央研究所 | プロテーゼ製作具 |
AU678350B2 (en) | 1992-05-08 | 1997-05-29 | Schneider (Usa) Inc. | Esophageal stent and delivery tool |
CA2152594C (en) | 1993-01-19 | 1998-12-01 | David W. Mayer | Clad composite stent |
TW353123B (en) | 1993-03-23 | 1999-02-21 | Murata Machinery Ltd | Braider a braider having a mandrel support member which is pivotable around a braiding point and linearly movable toward and away from the braiding point |
RU2089131C1 (ru) | 1993-12-28 | 1997-09-10 | Сергей Апполонович Пульнев | Стент |
WO1995029646A1 (en) | 1994-04-29 | 1995-11-09 | Boston Scientific Corporation | Medical prosthetic stent and method of manufacture |
US5591226A (en) | 1995-01-23 | 1997-01-07 | Schneider (Usa) Inc. | Percutaneous stent-graft and method for delivery thereof |
US5575818A (en) | 1995-02-14 | 1996-11-19 | Corvita Corporation | Endovascular stent with locking ring |
BE1009277A3 (fr) * | 1995-04-12 | 1997-01-07 | Corvita Europ | Tuteur auto-expansible pour dispositif medical a introduire dans une cavite d'un corps, et son procede de preparation. |
ATE218052T1 (de) | 1995-11-27 | 2002-06-15 | Schneider Europ Gmbh | Stent zur anwendung in einem körperlichen durchgang |
US6241757B1 (en) * | 1997-02-04 | 2001-06-05 | Solco Surgical Instrument Co., Ltd. | Stent for expanding body's lumen |
US5906641A (en) * | 1997-05-27 | 1999-05-25 | Schneider (Usa) Inc | Bifurcated stent graft |
CA2424551A1 (en) * | 1997-05-27 | 1998-11-27 | Schneider (Usa) Inc. | Stent and stent-graft for treating branched vessels |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6520983B1 (en) * | 1998-03-31 | 2003-02-18 | Scimed Life Systems, Inc. | Stent delivery system |
DE19843822A1 (de) * | 1998-09-24 | 2000-03-30 | Impag Gmbh Medizintechnik | Vorrichtung zum Herstellen eines Stents |
US7018401B1 (en) * | 1999-02-01 | 2006-03-28 | Board Of Regents, The University Of Texas System | Woven intravascular devices and methods for making the same and apparatus for delivery of the same |
WO2000044309A2 (en) * | 1999-02-01 | 2000-08-03 | Board Of Regents, The University Of Texas System | Woven bifurcated and trifurcated stents and methods for making the same |
US6510961B1 (en) | 1999-04-14 | 2003-01-28 | A&P Technology | Integrally-reinforced braided tubular structure and method of producing the same |
DE19941669C2 (de) * | 1999-09-01 | 2001-10-25 | Raedlinger Maschinen Und Anlag | Gewebeschlauch für Hochdruckfluidleitungen sowie Verfahren zur Erhöhung der Nenndruckstufe von Altfluidleitungen |
US6585758B1 (en) * | 1999-11-16 | 2003-07-01 | Scimed Life Systems, Inc. | Multi-section filamentary endoluminal stent |
US6622604B1 (en) | 2000-01-31 | 2003-09-23 | Scimed Life Systems, Inc. | Process for manufacturing a braided bifurcated stent |
US6325822B1 (en) * | 2000-01-31 | 2001-12-04 | Scimed Life Systems, Inc. | Braided stent having tapered filaments |
US6652571B1 (en) | 2000-01-31 | 2003-11-25 | Scimed Life Systems, Inc. | Braided, branched, implantable device and processes for manufacture thereof |
US6613078B1 (en) * | 2000-08-02 | 2003-09-02 | Hector Daniel Barone | Multi-component endoluminal graft assembly, use thereof and method of implanting |
US20030135265A1 (en) * | 2002-01-04 | 2003-07-17 | Stinson Jonathan S. | Prostheses implantable in enteral vessels |
US7029494B2 (en) * | 2002-02-08 | 2006-04-18 | Scimed Life Systems, Inc. | Braided modular stent with hourglass-shaped interfaces |
WO2004001780A2 (en) * | 2002-06-20 | 2003-12-31 | Federal-Mogul Powertrain, Inc. | Multiple layer insulating sleeve |
US7001425B2 (en) * | 2002-11-15 | 2006-02-21 | Scimed Life Systems, Inc. | Braided stent method for its manufacture |
US20040102855A1 (en) | 2002-11-21 | 2004-05-27 | Scimed Life Systems, Inc. | Anti-reflux stent |
US7323001B2 (en) * | 2003-01-30 | 2008-01-29 | Ev3 Inc. | Embolic filters with controlled pore size |
CA2526382C (en) | 2003-05-23 | 2013-01-15 | Scimed Life Systems, Inc. | Stents with attached looped ends |
DE10335649A1 (de) * | 2003-07-30 | 2005-02-24 | Jotec Gmbh | Flechtstent zur Implantation in ein Blutgefäß |
US20070293927A1 (en) * | 2004-02-17 | 2007-12-20 | The Children's Hospital Of Philadelphia | Gene and Cell Delivery Self Expanding Polymer Stents |
US20050203606A1 (en) * | 2004-03-09 | 2005-09-15 | Vancamp Daniel H. | Stent system for preventing restenosis |
US7993387B2 (en) | 2004-05-14 | 2011-08-09 | Boston Scientific Scimed, Inc. | Stent with reduced weld profiles and a closed-end wire configuration |
US20060206200A1 (en) * | 2004-05-25 | 2006-09-14 | Chestnut Medical Technologies, Inc. | Flexible vascular occluding device |
ES2607402T3 (es) * | 2004-05-25 | 2017-03-31 | Covidien Lp | Dispositivo de oclusión vascular flexible |
JP5009163B2 (ja) | 2004-11-10 | 2012-08-22 | ボストン サイエンティフィック リミテッド | 配備に要する力を減じた外傷回避ステントと、その製造方法と、ステント搬送配備システム |
US9545300B2 (en) * | 2004-12-22 | 2017-01-17 | W. L. Gore & Associates, Inc. | Filament-wound implantable devices |
KR100633020B1 (ko) * | 2005-07-15 | 2006-10-11 | 주식회사 스텐다드싸이텍 | 스텐트 및 그의 제작 방법 |
US7655035B2 (en) * | 2005-10-05 | 2010-02-02 | Boston Scientific Scimed, Inc. | Variable lamination of vascular graft |
DE102006040301A1 (de) * | 2005-12-06 | 2008-03-06 | Düring, Klaus, Dr. | Vorrichtung zur Schienung eines Hohlraums, Organwegs und/oder Gefäßes |
US20070179590A1 (en) * | 2005-12-29 | 2007-08-02 | Wenfeng Lu | Hybrid intraluminal device with varying expansion force |
US8900287B2 (en) * | 2006-01-13 | 2014-12-02 | Aga Medical Corporation | Intravascular deliverable stent for reinforcement of abdominal aortic aneurysm |
EP1849440A1 (en) | 2006-04-28 | 2007-10-31 | Younes Boudjemline | Vascular stents with varying diameter |
US8535368B2 (en) * | 2006-05-19 | 2013-09-17 | Boston Scientific Scimed, Inc. | Apparatus for loading and delivering a stent |
CN200939184Y (zh) * | 2006-08-22 | 2007-08-29 | 茅爱武 | 由异型丝材编织的医用支架 |
JP2008067922A (ja) * | 2006-09-14 | 2008-03-27 | Homuzu Giken:Kk | ステント |
WO2008091409A1 (en) * | 2007-01-25 | 2008-07-31 | Boston Scientific Limited | Endoscope with preloaded or preloadable stent |
US8048147B2 (en) * | 2007-06-27 | 2011-11-01 | Aga Medical Corporation | Branched stent/graft and method of fabrication |
CZ303081B6 (cs) | 2007-12-13 | 2012-03-21 | Ella-Cs, S. R. O. | Zpusob výroby samoexpanzního biodegradabilního stentu |
CN201150578Y (zh) * | 2007-12-26 | 2008-11-19 | 上海康德莱企业发展集团有限公司 | 一种编织血管支架 |
US8623071B2 (en) * | 2008-01-07 | 2014-01-07 | DePuy Synthes Products, LLC | Radiopaque super-elastic intravascular stent |
CA2710561C (en) * | 2008-01-17 | 2019-01-08 | Boston Scientific Scimed, Inc. | Stent with anti-migration feature |
US8114147B2 (en) * | 2008-06-16 | 2012-02-14 | Boston Scientific Scimed, Inc. | Continuous double layered stent for migration resistance |
US8151682B2 (en) * | 2009-01-26 | 2012-04-10 | Boston Scientific Scimed, Inc. | Atraumatic stent and method and apparatus for making the same |
WO2011137043A1 (en) * | 2010-04-30 | 2011-11-03 | Boston Scientific Scimed, Inc. | Apparatus and method for manufacturing a single wire stent |
US8621975B2 (en) * | 2011-09-20 | 2014-01-07 | Aga Medical Corporation | Device and method for treating vascular abnormalities |
US11623438B2 (en) * | 2012-01-16 | 2023-04-11 | Merit Medical Systems, Inc. | Rotational spun material covered medical appliances and methods of manufacture |
JP6346861B2 (ja) * | 2012-04-06 | 2018-06-20 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | 内部人工器官およびその製造方法 |
US9526640B2 (en) * | 2013-08-18 | 2016-12-27 | Boston Scientific Scimed, Inc. | Anti-migration micropatterned stent coating |
US9452070B2 (en) * | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
WO2014150130A1 (en) * | 2013-03-15 | 2014-09-25 | Merit Medical Systems, Inc. | Esophageal stent |
JP6171719B2 (ja) * | 2013-08-21 | 2017-08-02 | 株式会社カネカ | ステント加工治具及びステントの製造方法 |
KR101837113B1 (ko) * | 2013-11-08 | 2018-03-09 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | 관내 디바이스 |
US10470904B2 (en) * | 2016-05-18 | 2019-11-12 | Boston Scientific Scimed, Inc. | Stent retrieval system |
EP3595594B1 (en) * | 2017-03-15 | 2024-09-18 | Merit Medical Systems, Inc. | Transluminal stents |
-
2009
- 2009-12-03 US US12/630,068 patent/US8151682B2/en active Active
-
2010
- 2010-01-26 CN CN2010800140331A patent/CN102362023B/zh active Active
- 2010-01-26 ES ES10702784T patent/ES2701650T3/es active Active
- 2010-01-26 CA CA2750763A patent/CA2750763C/en not_active Expired - Fee Related
- 2010-01-26 ES ES17202534T patent/ES2909905T3/es active Active
- 2010-01-26 KR KR1020117019662A patent/KR101663787B1/ko active IP Right Grant
- 2010-01-26 EP EP21216706.8A patent/EP3998379A1/en active Pending
- 2010-01-26 KR KR1020167011024A patent/KR101725305B1/ko active IP Right Grant
- 2010-01-26 EP EP10702784.9A patent/EP2391752B1/en active Active
- 2010-01-26 EP EP17202534.8A patent/EP3321402B1/en active Active
- 2010-01-26 AU AU2010206532A patent/AU2010206532B2/en not_active Ceased
- 2010-01-26 WO PCT/US2010/022082 patent/WO2010085794A2/en active Application Filing
- 2010-01-26 KR KR1020167027136A patent/KR101801381B1/ko active IP Right Grant
- 2010-01-26 JP JP2011548215A patent/JP5640018B2/ja active Active
- 2010-01-26 CN CN201310611220.3A patent/CN103603134B/zh active Active
- 2010-01-26 KR KR1020177001048A patent/KR101801379B1/ko active IP Right Grant
-
2012
- 2012-04-06 US US13/441,649 patent/US8459164B2/en active Active
-
2013
- 2013-06-07 US US13/912,445 patent/US8677874B2/en active Active
- 2013-12-04 US US14/096,307 patent/US9388517B2/en active Active
-
2014
- 2014-05-01 JP JP2014094637A patent/JP5873890B2/ja active Active
-
2016
- 2016-01-18 JP JP2016006898A patent/JP6215367B2/ja active Active
- 2016-07-07 US US15/204,508 patent/US10278842B2/en active Active
-
2019
- 2019-03-26 US US16/364,772 patent/US10947651B2/en active Active
-
2021
- 2021-02-22 US US17/181,474 patent/US11578437B2/en active Active
-
2023
- 2023-01-24 US US18/158,821 patent/US11840780B2/en active Active
- 2023-12-05 US US18/529,513 patent/US20240125020A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405377A (en) * | 1992-02-21 | 1995-04-11 | Endotech Ltd. | Intraluminal stent |
JP2001517536A (ja) * | 1997-10-01 | 2001-10-09 | ボストン サイエンティフィック リミテッド | 柔軟な金属ワイヤステント |
JP2002535075A (ja) * | 1999-02-01 | 2002-10-22 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 織物血管内デバイスおよびその製法およびその搬送用装置 |
JP2004519307A (ja) * | 2001-04-04 | 2004-07-02 | テウング メディカル カンパニー リミテッド | 形状記憶合金を用いた可変状態保持型拡張機構およびその製造方法並びに拡張機構製造機 |
JP2006506201A (ja) * | 2002-11-20 | 2006-02-23 | ユーヌ・ブージェムラン | メッシュ状構造を有した医療用インプラントの製造方法ならびにこの製造方法によって得られたインプラント |
US20040193141A1 (en) * | 2003-02-14 | 2004-09-30 | Leopold Eric W. | Intravascular flow modifier and reinforcement device and deployment system for same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11840780B2 (en) | Atraumatic stent and method and apparatus for making the same | |
US10028850B2 (en) | Endoprosthesis with filament repositioning of retrieval member and guard structure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5873890 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |